INmune Bio Inc. (INMB) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 34% of 52W Range • RSI-14 at 34.5 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While INMB currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.99) and Max Pain ($1.68) forces dealer call-delta covering toward $2.73.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
INmune Bio Inc. (INMB) surged +4.58% to $1.60, trading at 34% of its 52-week range ($1.09 – $2.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, Oct. 29, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on in
BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a de
INmune Bio (NASDAQ:INMB) is advancing its European commercialization strategy for Ebstrocel, leveraging chemistry, manufacturing, and controls (CMC) progress to streamline its regulatory timeline and accelerate potential
Final pre-MAA package submitted to MHRA on October 20, 2026Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeksU.S. BLA
Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NAS
INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INMB today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INMB. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, INmune Bio Inc. (INMB) ranks #488 by composite RQD confidence (45/100, grade D) and #766 by equity capitalization ($44.4M). Within this direct 5-issuer industry benchmark cohort, INMB leads on earnings valuation at N/A trailing P/E, while INMB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with INMB at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INMB
ACTIVE
INmune Bio Inc. | D | 45/100 | — | — | -35.0% | +4.58% | $44.4M | Benchmark Subject |
| IMA ImageneBio Inc. | E | 24/100 | — | — | -35.0% | -3.57% | $46.0M | /ima-vs-inmb → |
| LONA LeonaBio Inc. | D- | 42/100 | — | — | -35.0% | -1.01% | $46.3M | /lona-vs-inmb → |
| TIL Instil Bio Inc. | D | 51/100 | — | — | -35.0% | +0.52% | $46.3M | /til-vs-inmb → |
| CRBU Caribou Biosciences Inc. | D- | 43/100 | — | — | -35.0% | -9.07% | $47.7M | /crbu-vs-inmb → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), INmune Bio Inc. (INMB) reported GAAP revenue of $50.0K (+257.1% vs. FY2024 revenue of $14.0K , and -67.7% cumulative change since FY2023) , GAAP net income of -$46.0M, operating cash flow of -$22.6M, and free cash flow of -$23.6M (+29.2% YoY). On the balance sheet, INMB closed FY2025 with $32.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $50.0K | -$46.0M | -$22.6M | -$23.6M | $32.4M | — |
| FY2024 (FY) | 2024-12-31 | $14.0K | -$42.0M | -$33.4M | -$33.4M | $39.6M | — |
| FY2023 (FY) | 2023-12-31 | $155.0K | -$30.0M | -$12.0M | -$12.0M | — | — |
As of 2026-11-01, INmune Bio Inc. (NASDAQ: INMB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.60 (+4.58% 1D, market cap $44.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INMB ranks #488 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INMB carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMA (ImageneBio Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $46.0M) and LONA (LeonaBio Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M). Among the 5-stock peer group, INMB leads on earnings multiple (N/A) while INMB leads on capital efficiency (-35.0% ROIC).
Per INMB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711754), INmune Bio Inc. generated $50.0K in revenue (+257.1% YoY), -$46.0M in net income, and -$23.6M in free cash flow against $32.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
INMB last traded at $1.60 (+4.58% on volume of 185,890 shares), positioning the stock -19.60% below its 50-day simple moving average ($1.99) and -2.44% below its 200-day simple moving average ($1.64). Across its 52-week range of $1.09 to $2.60, INMB sits at the 33.8% percentile with a 14-day RSI of 34.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.40 to $1.80).
Why INMB Stock surged +4.58% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.